PARP Inhibitors in Ovarian Cancer
Martina Murphy, MD, discusses PARP inhibitors in ovarian cancer. She examines the use of a PARP inhibitor as first-line therapy, and helps us to understand the relevance of homologous recombination deficiency (HRD) in development of ovarian cancer. She shares the mechanism of action and rationale for PARPi and reviews the FDA-approved uses for PARPi in the management of advanced ovarian cancer.
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.